UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Clinical cancer research, 2009-11, Vol.15 (22), p.7085-7091

2009

Link zum Volltext

Verfügbarkeit prüfen

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Clinical cancer research, 2016-12, Vol.22 (23), p.5829-5838

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

The New England journal of medicine, 2013-08, Vol.369 (6), p.507-516

2013

Link zum Volltext

Verfügbarkeit prüfen

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

British journal of haematology, 2012-09, Vol.158 (6), p.739-748

2012

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Clinical cancer research, 2012-09, Vol.18 (17), p.4830-4840

2012

Link zum Volltext

Verfügbarkeit prüfen

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Journal of clinical oncology, 2014-06, Vol.32 (17), p.1797-1803

2014

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2012-10, Vol.12 (5), p.310-318

2012

Link zum Volltext

Verfügbarkeit prüfen

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Annals of hematology, 2015-02, Vol.94 (2), p.249-256

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

Clinical cancer research, 2010-03, Vol.16 (5), p.1673-1681

2010

Link zum Volltext

Verfügbarkeit prüfen

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS449-TPS449

2021

Link zum Volltext

Verfügbarkeit prüfen

Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7057-7057

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract A6: Association of clinical outcomes and the change in circulating soluble VEGF receptor 2 (VEGFR2) levels in advanced gastric cancer patients treated with telatinib (Tel), capecitabine (X), and cislatin (P)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A6-A6

2011

Link zum Volltext

Verfügbarkeit prüfen

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8035-8035

2012

Link zum Volltext

Verfügbarkeit prüfen

An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients

Cancer, 1996-12, Vol.78 (11), p.2421-2426

1996

Link zum Volltext

Verfügbarkeit prüfen

Acquired circulating anticoagulants

Hematology/oncology clinics of North America, 1992-12, Vol.6 (6), p.1341

Kunkel, L A

1992

Link zum Volltext

Verfügbarkeit prüfen

Acquired Circulating Anticoagulants in Malignancy

Seminars in thrombosis and hemostasis, 1992-01, Vol.18 (4), p.416-423

Kunkel, Lori A.

1992

Link zum Volltext

Verfügbarkeit prüfen

Autoimmune anemia, neutropenia, Eaton-Lambert syndrome, and cerebellar degeneration in a patient with lymphoid hyperplasia

Southern medical journal (Birmingham, Ala.), 1994-02, Vol.87 (2), p.263-264

1994

Link zum Volltext

Verfügbarkeit prüfen

Metabolic inhibitors render ‘resistant’ target cells sensitive to natural killer cell‐mediated lysis

International journal of cancer, 1981-01, Vol.27 (1), p.73-79

1981

Link zum Volltext

Verfügbarkeit prüfen

CD34+ cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection

Journal of hematotherapy, 1998-04, Vol.7 (2), p.175-183

1998

Link zum Volltext

Verfügbarkeit prüfen

Distinctive patterns of microRNA expression in primary muscular disorders

Proceedings of the National Academy of Sciences - PNAS, 2007-10, Vol.104 (43), p.17016-17021

2007

Link zum Volltext

Verfügbarkeit prüfen

IVIG Compared With IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children

Pediatrics (Evanston), 2021-12, Vol.148 (6), p.1

2021

Link zum Volltext

Verfügbarkeit prüfen

Loop analysis of the anal sphincter complex in fecal incontinent patients using functional luminal imaging probe

American journal of physiology: Gastrointestinal and liver physiology, 2020-01, Vol.318 (1), p.G66-G76

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 90

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(82)

Publikationsform

Artikel
(89)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Humans
(37)
Life Sciences & Biomedicine
(37)
Female
(22)
Male
(22)
Middle Aged
(22)
Adult
(21)
Aged
(21)
Biological And Medical Sciences
(19)
Oncology
(19)
Medical Sciences
(18)
Hematology
(14)
Pharmacology. Drug Treatments
(10)
Antineoplastic Agents
(9)
Aged, 80 And Over
(8)
Hematologic And Hematopoietic Diseases
(8)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(8)
Antineoplastic Agents - Adverse Effects
(7)
Antineoplastic Agents - Therapeutic Use
(7)
Dose-Response Relationship, Drug
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy

Abstract A6: Association of clinical outcomes and the change in circulating soluble VEGF receptor 2 (VEGFR2) levels in advanced gastric cancer patients treated with telatinib (Tel), capecitabine (X), and cislatin (P)

A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1

An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients

Acquired circulating anticoagulants

Acquired Circulating Anticoagulants in Malignancy

Autoimmune anemia, neutropenia, Eaton-Lambert syndrome, and cerebellar degeneration in a patient with lymphoid hyperplasia

Metabolic inhibitors render ‘resistant’ target cells sensitive to natural killer cell‐mediated lysis

CD34+ cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection

Distinctive patterns of microRNA expression in primary muscular disorders

IVIG Compared With IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children

Loop analysis of the anal sphincter complex in fecal incontinent patients using functional luminal imaging probe

Suchergebnisse filtern